---
title: "AFT Pharmaceuticals appoints new CFO to support global growth"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286682956.md"
description: "AFT Pharmaceuticals has appointed Stuart Houliston as the new CFO, effective June 15, 2026, succeeding Malcolm Tubby. Houliston, previously with Sanford and KPMG, is expected to enhance the company's global growth strategy. AFT Pharmaceuticals is New Zealand's largest pharmaceutical company, offering a wide range of medicines across various markets."
datetime: "2026-05-17T21:17:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286682956.md)
  - [en](https://longbridge.com/en/news/286682956.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286682956.md)
---

# AFT Pharmaceuticals appoints new CFO to support global growth

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

AFT Pharmaceuticals Ltd. ( (NZ:AFT) ) has provided an announcement.

AFT Pharmaceuticals, New Zealand’s largest domestic pharmaceuticals company, has appointed Stuart Houliston as its new Chief Financial Officer, effective 15 June 2026. He replaces long-serving CFO Malcolm Tubby, who will retire on 29 May, with executive Simon Bosley covering the role in the interim.

Houliston joins from Sanford, the country’s largest integrated fishing and aquaculture group, and brings experience in public markets and audit from his previous role as an audit director at KPMG. AFT’s board and management highlighted his financial expertise as critical to supporting the company’s global growth strategy, underscoring the importance of the CFO transition for sustaining momentum in its expanding international pharmaceuticals business.

**More about AFT Pharmaceuticals Ltd.**

AFT Pharmaceuticals is a New Zealand-based multinational pharmaceutical company that develops, markets and distributes a broad portfolio of proprietary and in-licensed medicines across multiple therapeutic categories. Its products, spanning patented, branded and generic drugs, are sold through over-the-counter, prescription and hospital channels in Australia, New Zealand, parts of Asia, North America and Europe, with additional out-licensing to partners in more than 125 countries.

**YTD Price Performance:** 3.25%

**Average Trading Volume:** 11,955

**Technical Sentiment Signal:** Buy

**Current Market Cap:** N$366M

See more insights into AFT stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [AFP.AU](https://longbridge.com/en/quote/AFP.AU.md)

## Related News & Research

- [AFT Pharmaceuticals Targets Minimum $300m Revenue After Record Earnings](https://longbridge.com/en/news/287149533.md)
- [15:00 ETKiwi-Born Legal AI Company Ivo Partners with New Zealand Football as Global Expansion Accelerates](https://longbridge.com/en/news/288761980.md)
- [Kazia Therapeutics Appoints James Levine as Chief Financial Officer | KZIA Stock News](https://longbridge.com/en/news/288415510.md)
- [Wockhardt soars 19%, zooms 75% in 1 month; what's driving pharma stock?](https://longbridge.com/en/news/288213295.md)
- [New Zealand Q1 terms of trade fell, April building permits rose](https://longbridge.com/en/news/288488499.md)